Pages that link to "Q42223690"
Jump to navigation
Jump to search
The following pages link to Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration (Q42223690):
Displaying 45 items.
- Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies (Q26865838) (← links)
- Treating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristine (Q27000078) (← links)
- Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data (Q31143912) (← links)
- Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies (Q33558141) (← links)
- International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (Q33822004) (← links)
- Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody (Q33893777) (← links)
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study (Q34042800) (← links)
- Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians (Q35820095) (← links)
- Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment (Q36350443) (← links)
- The myth of the second remission of acute leukemia in the adult (Q36619678) (← links)
- Comprehensive craniospinal radiation for controlling central nervous system leukemia (Q36905115) (← links)
- Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia (Q37325019) (← links)
- Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates (Q38095113) (← links)
- Emerging drugs for acute lymphocytic leukemia (Q38172586) (← links)
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial (Q38371346) (← links)
- Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab (Q38639698) (← links)
- Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions (Q38728592) (← links)
- Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review (Q38840247) (← links)
- Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells (Q38945853) (← links)
- Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. (Q40151539) (← links)
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia (Q40312849) (← links)
- Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (Q40591760) (← links)
- Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia (Q41009415) (← links)
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. (Q42277162) (← links)
- An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. (Q45971930) (← links)
- Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Q46176860) (← links)
- Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission (Q47873097) (← links)
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (Q49553520) (← links)
- Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia. (Q49688800) (← links)
- Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. (Q49897464) (← links)
- Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia (Q50043284) (← links)
- CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. (Q55193924) (← links)
- Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy (Q57045402) (← links)
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage (Q57279955) (← links)
- Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. (Q64996641) (← links)
- Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia (Q89321114) (← links)
- Recent Advances in the Management of Acute Lymphoblastic Leukaemia (Q89870947) (← links)
- Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? (Q90312347) (← links)
- Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party (Q90590329) (← links)
- Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (Q90626791) (← links)
- When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Q90794508) (← links)
- Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study (Q92214898) (← links)
- Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab (Q95846580) (← links)
- CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 Relapsed/Refractory Malignancies (Q100429962) (← links)
- Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia (Q103811864) (← links)